IL-5
Eosinophil survival factor
- Expression
- Elevated
- Evidence level
- established
- Targeted by
- Mepolizumab, Benralizumab (via IL-5Rα)
Role in pathogenesis
IL-5 is the master regulator of eosinophil biology: drives maturation, tissue recruitment, activation, and survival. Elevated IL-5 correlates with polyp recurrence. Targeted by mepolizumab and indirectly by benralizumab.
Targeting drugs (2)
| Drug | Mechanism | Response | Line |
|---|---|---|---|
| Mepolizumab | Anti–IL-5 monoclonal antibody | Significant NPS reduction | 1st-line biologic |
| Benralizumab | Anti–IL-5Rα monoclonal antibody (ADCC-mediated eosinophil depletion) | Near-complete eosinophil depletion | 1st-line biologic |